TITLE

CLINIC ROUNDUP

PUB. DATE
September 2008
SOURCE
BioWorld Today;9/19/2008, Vol. 19 Issue 183, p7
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
This section offers news briefs on the pharmaceutical industry. Avigen Inc. has completed the double-blind portion of its Phase IIb trial for AV650 used in the treatment of spasticity linked to multiple sclerosis. Positive results were reported by Incyte Corp. from Phase IIa trials of topical INCB18424, a selective janus-associated kinase (JAK) inhibitor. Multicenter Phase I trials of SB1518, an orally active JAK2 inhibitor, were initiated by S*BIO Pte. Ltd.
ACCESSION #
34470968

 

Related Articles

  • European Haematology Association.  // BioWorld Today;6/15/2010, Vol. 21 Issue 114, p4 

    The article reports on the Phase I/II dose escalation trial of S*BIO Pte. Ltd.'s oral JAK2 inhibitor SB1518 which drew positive safety, tolerability and pharmacokinetic/pharmacodynamic findings.

  • S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p1 

    The article reports that the clinical trial of the novel anti-cancer drug was initiated by the S*BIO Pte Ltd. in Singapore. The SB939 is a histone deacetylase (HDAC) inhibitor which is a targeted anti-cancer therapeutics. The SB939 Phase I trial was conducted to determine its pharmacokinetic and...

  • Singapore's S*BIO Adds $26M for Phase II Studies in Cancer. Hollingsworth, Catherine // BioWorld Today;10/21/2008, Vol. 19 Issue 205, p1 

    The article reports that S*BIO Pte. Ltd. has raised $26 million to fund phase II trials for the SB939 and SB1518 cancer drugs in 2008. The financing was led by Bio*One Capital, a member of the Singapore Economic Development Authority and Aravis Venture. In a statement, chief executive Jan Anders...

  • Correction.  // BioWorld Today;4/6/2007, Vol. 18 Issue 67, p2 

    A correction to the misidentification of the location of the headquarters of the company S*BIO Pte. Ltd. that was published in the April 4, 2007 issue is presented.

  • S*BIO Adds $26M for Phase II Cancer Studies.  // Bioworld Week;10/27/2008, Vol. 16 Issue 43, p3 

    The article reports on the $26 million funds raised by S☆BIO Pte. Ltd. in 2008. The company raised $26 million in a Series B financing round, which will be used mainly to move its lead compound for cancer, SB939 and SB1518, into Phase II trials. SB939, currently in Phase I testing in both...

  • S*BIO ADVANCES JAK2 INHIBITOR SB1518 INTO PHASE 1/2 TRIAL.  // Worldwide Biotech;Jan2009, Vol. 21 Issue 1, p4 

    The article reports on the initiation of a Phase ½ clinical trial of JAK2-selective kinase inhibitor drug SB1518 in patients with chronic idiopathic myelofibrosis (CIMF) in Australia in January 2009. The trial, launched by Singaporean company S*BIO Pte Ltd., will be conducted in two phases....

  • Avigen reports positive data from pain relief and drug addiction trials.  // PharmaWatch: CNS;Apr2009, Vol. 8 Issue 4, p15 

    The article reports on the positive data of two preclinical trials of biopharmaceutical company Avigen Inc. The first study investigated the effect of glial attenuator drugs in altering the analgesic efficacy of opioids, which indicated that glial attenuators suppress the opiod withdrawal...

  • Avigen's Phase IIb spasticity trial fails endpoint.  // PharmaWatch: CNS;Dec2008, Vol. 7 Issue 12, p9 

    The article reports on the Avigen Inc.'s Phase IIb study of AV650 for the treatment of spasticity associated with multiple sclerosis, in which the drug did not achieve statistical significance on its primary endpoint of a reduction from baseline of patients' Ashworth scores as compared to...

  • S*BIO/UNIVERSITY OF SINGAPORE PARTNER ON TUMOR BIOAMARKER.  // Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p7 

    The article focuses on the two-year research partnership forged by S*BIO Pte Ltd. with the National University Hospital-National University of Singapore Tissue Repository (NUH-NUS TR). The partnership is aimed at conducting biomarker research and at evaluating the responsiveness of tumors to the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics